MedPath

ONLIFE- Smartphone use and diagnosis of depressio

Conditions
F32
Recurrent depressive disorder
Dysthymia
F33
F34.1
Depressive episode
Registration Number
DRKS00010705
Lead Sponsor
eiter der Sektion Psychosomatische Medizin und PsychotherapieKlinik und Poliklinik für Psychiatrie und Psychotherapie der LMU München
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
400
Inclusion Criteria

Patients: Diagnosis of Depression (F32.x, F33.x, F34.1), ambulant/stationary psychotherapeutic/psychiatric treatment

Control subjects: Physical and mental healthy subjects without mental diseases in their ananmnesis.

Exclusion Criteria

Patients: acute suicidal tendency, substance addiction, pregnancy, serious physical/somatic diseases, psychotic disorders, bipolar disorder, insufficient german language skills; Primary Diagnosis: panic disorder, GAD, social phobia, PTSD

Control subjects: intake of psychiatric medication, serious physical diseases, pregnancy, psychiatric diagnosis

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
-Measuring depression-specific symptoms (IDCL, BDI-II), personality variables (NEO-FFI), Instruments covering fear, anger, emotionregulation (DERS, STAI, STAXI), resilience (CD-Risc), trauma (CTQ), social networking (SNI), smartphone addiction (SAS-SV) <br><br>All of this standardized questionnaires will be measured at two times of measurement (at baseline and 6 months later) <br><br>- Gathering Smartphonedata an their changes regarding depressiv symptoms for 6 Months (GPS, Phoneuse, Calls, SMS/Mails, Apps and Appuse, vibration / mute, Notifications, calendar items, reminders, WLAN On/Off, flightmode on/off, music, frequency of taking pictures and videos, Bluetooth).
Secondary Outcome Measures
NameTimeMethod
Differences in covered data regarding chronic / episodic depressive patients and construction of a new test for chronic depression.
© Copyright 2025. All Rights Reserved by MedPath